Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Stress and the risk of multiple sclerosis.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Fingolimod modulates microglial activation to augment markers of remyelination.
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Multiple sclerosis.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.

Pages